• CUDC-907: In Vitro Workflow and QC Guide

  2026-08-24

  CUDC-907 is a dual PI3K and HDAC inhibitor for controlled in vitro studies of PI3K/AKT signaling, histone deacetylase activity, apoptosis, and cell-cycle behavior. This guide translates the product dossier into practical handling and assay guidance while defining limits: it is for scientific research only, not diagnostic, therapeutic, or clinical use.

• Caspase-6 as a Translational Control Point

  2026-08-24

  Z-VEID-FMK offers a practical route to interrogate caspase-6 biology across apoptosis, neuronal injury, inflammation, and emerging host–virus mechanisms. This article connects inhibitor strategy with evidence from PRRSV research while defining the controls, limitations, and translational decisions needed to turn pathway inhibition into reliable mechanistic insight.

• HDAC8-Driven AKT Bypass of MEK1/2 Inhibition

  2026-08-23

  The reference study identifies an adaptive resistance circuit in which HDAC8 activates AKT through altered PLCB1 and DESC1 expression after MEK1/2–ERK suppression. Its combination of lethal toxin, U0126, transcriptomic profiling, and genetic validation provides a mechanistic framework for studying resistance to MAPK-targeted treatment in colorectal cancer and melanoma models.

• NVP-BGJ398 Phosphate: An FGFR3 Assay Framework

  2026-08-22

  NVP-BGJ398 phosphate is a selective FGFR1–3 inhibitor for dissecting pathway-dependent phenotypes. This article presents a signal-to-phenotype assay framework grounded in cancer models and SLC26A2-related skeletal disease research.

• NVP-BGJ398 Phosphate: FGFR Evidence and Use

  2026-08-22

  NVP-BGJ398 phosphate is a selective FGFR1–3 inhibitor with nanomolar biochemical potency and reported activity in FGFR-altered cancer models. BGJ-398 phosphate also inhibits pathological FGFR3 signaling in a mouse model of SLC26A2-related chondrodysplasia, but these preclinical findings do not establish clinical efficacy.

• Netarsudil (AR-13324) Workflow for ROCK and siRNA

  2026-08-21

  Netarsudil (AR-13324) is a potent ROCK pathway probe for modeling actin remodeling, trabecular meshwork biology, and aqueous humor outflow regulation. Its predicted ability to complex siRNA also creates a practical formulation path for testing combined small-molecule and RNA interventions in fibrotic ocular cell models.

• Pazopanib (GW-786034) in ATRX-Deficient Glioma

  2026-08-20

  Pazopanib (GW-786034) offers a practical way to interrogate VEGF, PDGFR, and related receptor tyrosine kinase signaling in endothelial, glioma, and combination-treatment assays. This workflow translates evidence from ATRX-deficient high-grade glioma models into reproducible dosing, readout, and troubleshooting strategies for cancer research.

• Busulfan A8386: Reliable Senescence Models

  2026-08-20

  Learn how Busulfan (SKU A8386) supports reproducible senescence, viability, and germ-cell depletion workflows through defined DNA crosslinking, solvent guidance, and storage recommendations. This scenario-based guide connects practical assay design with recent genetic-tracing evidence in mouse ovaries.

• Veratridine Workflows for Sodium Channel Research

  2026-08-19

  Veratridine is a voltage-gated sodium channel opener that converts channel inactivation into a controllable model of persistent depolarization. This guide translates that mechanism into practical workflows for sodium channel dynamics research, excitotoxicity studies, blocker screening, and carefully bounded oncology applications.

• MK-4827: A Decision Framework for PARP Assays

  2026-08-19

  MK-4827 (Niraparib) enables precise PARP-1/-2 inhibition while revealing how BRCA2 functional status shapes DNA damage responses. This article presents an assay-design framework based on hyperthermia-induced PARP inhibitor sensitization in ovarian cancer models.

• SCH772984 HCl: ERK1/2 Inhibitor Workflows

  2026-08-18

  SCH772984 HCl is a selective ERK1/2 inhibitor for mapping pathway reactivation, testing resistance, and measuring antiproliferative responses in BRAF- and RAS-driven models. This workflow-focused guide also shows how to connect ERK pharmacology with exploratory TERT and APEX2 assays without overstating the current evidence.

• IPA-3: A Translational Lens on Pak1 Signaling

  2026-08-18

  A mechanistic and strategic guide to using IPA-3 for Pak1 pathway interrogation, kinase assays, cell signaling, neuroinflammation, cancer biology, and evidence-based translational decisions.

• Gentamycin Sulfate: Workflows for Resistance Research

  2026-08-17

  Build reproducible assays for bacterial protein synthesis, ribosome function, and resistance phenotyping with a water-soluble aminoglycoside antibiotic. This guide shows how to use Gentamycin Sulfate as a mechanistic challenge, a comparator in Gram-negative models, and a stressor for resistance-selection workflows without treating its activity as a surrogate for newer antibiotics.

• LY364947: Designing Causal TGF-β Assays

  2026-08-17

  LY364947 is a TGF-β type I receptor kinase inhibitor for dissecting Smad signaling, EMT, and fibrosis models. This assay-centered guide connects receptor-level perturbation with recent evidence on Wnt/β-catenin and TGF-β crosstalk, emphasizing reproducible experimental decisions.

• TAK-715: A Practical p38 MAPK Inhibitor Workflow

  2026-08-16

  TAK-715 combines nanomolar p38α activity with a practical workflow for cytokine, stress-response, and rheumatoid arthritis research. This guide explains how to build cell-based assays, interpret phospho-signaling data, translate findings toward inflammation models, and troubleshoot selectivity, solubility, and timing problems.

8434 records 1/563 page Next 12345 下5页 Last page